Landsberg Bennett & Dubbaneh LLC Increases Stake in Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Landsberg Bennett & Dubbaneh LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 2.3% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 88,736 shares of the biopharmaceutical company’s stock after purchasing an additional 1,979 shares during the period. Landsberg Bennett & Dubbaneh LLC’s holdings in Pfizer were worth $3,214,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Morgan Stanley boosted its position in Pfizer by 2.4% during the 2nd quarter. Morgan Stanley now owns 46,536,777 shares of the biopharmaceutical company’s stock valued at $2,015,972,000 after buying an additional 1,071,897 shares during the period. Fisher Asset Management LLC boosted its position in Pfizer by 3.7% during the 2nd quarter. Fisher Asset Management LLC now owns 44,133,251 shares of the biopharmaceutical company’s stock valued at $1,911,852,000 after buying an additional 1,559,405 shares during the period. Nuveen Asset Management LLC boosted its position in Pfizer by 2,240.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock valued at $1,563,256,000 after buying an additional 34,544,423 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Pfizer by 2.5% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 35,948,881 shares of the biopharmaceutical company’s stock valued at $1,557,306,000 after buying an additional 868,839 shares during the period. Finally, California Public Employees Retirement System boosted its position in Pfizer by 5.3% during the 2nd quarter. California Public Employees Retirement System now owns 23,186,244 shares of the biopharmaceutical company’s stock valued at $1,004,428,000 after buying an additional 1,159,857 shares during the period. 71.69% of the stock is owned by institutional investors.

Shares of NYSE PFE opened at $36.11 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $46.47. The firm has a market capitalization of $197.40 billion, a PE ratio of 11.63, a price-to-earnings-growth ratio of 2.84 and a beta of 0.66. The firm has a fifty day simple moving average of $35.96 and a two-hundred day simple moving average of $39.94.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the business earned $0.77 EPS. The company’s revenue for the quarter was down 1.5% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.81 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a $0.36 dividend. The ex-dividend date is Thursday, November 7th. This represents a $1.44 annualized dividend and a yield of 3.99%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

Several equities research analysts have weighed in on PFE shares. UBS Group reissued a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research report on Monday, August 5th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research report on Tuesday, October 1st. Goldman Sachs Group reissued a “buy” rating and set a $49.00 price target on shares of Pfizer in a research report on Monday, June 17th. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a research report on Wednesday, August 28th. Finally, ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Twelve equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and an average target price of $45.20.

In other Pfizer news, Director Scott Gottlieb purchased 3,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was bought at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the purchase, the director now directly owns 3,000 shares in the company, valued at $104,160. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Pfizer Inc purchased 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was acquired at an average price of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: What is a SEC Filing?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Landsberg Bennett & Dubbaneh LLC Increases Stake in Pfizer Inc.
Landsberg Bennett & Dubbaneh LLC Increases Stake in Pfizer Inc.
Royal Bank of Canada Has $5.34 Million Holdings in Invesco S&P MidCap 400 Pure Value ETF
Royal Bank of Canada Has $5.34 Million Holdings in Invesco S&P MidCap 400 Pure Value ETF
Landsberg Bennett & Dubbaneh LLC Grows Stock Holdings in Nike Inc
Landsberg Bennett & Dubbaneh LLC Grows Stock Holdings in Nike Inc
First Trust Nasdaq Bank ETF  Stock Holdings Lifted by Royal Bank of Canada
First Trust Nasdaq Bank ETF Stock Holdings Lifted by Royal Bank of Canada
Landsberg Bennett & Dubbaneh LLC Reduces Stock Position in Proofpoint Inc
Landsberg Bennett & Dubbaneh LLC Reduces Stock Position in Proofpoint Inc
GlobalBoost-Y  Trading 61.4% Lower  Over Last Week
GlobalBoost-Y Trading 61.4% Lower Over Last Week


© 2006-2019 Ticker Report